PolTREG (PTG.WA) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Total funding raised: $16M

Market Cap: $22.3MFounded: 2011HQ: Gdańsk, Poland

Sector Ranking#67 in Cell & Gene Therapy #48 in Immunotherapy / Immuno-Oncology

Overview

PolTREG is a clinical-stage biotech leveraging over 17 years of foundational research to develop Treg-based therapies for autoimmune diseases, with the goal of restoring immune tolerance. Its lead asset, PTG007, is in clinical trials for Type 1 Diabetes and Multiple Sclerosis, and the company is building a next-generation pipeline of engineered CAR-Tregs. Strategically, PolTREG aims to become a global leader in the field, supported by its proprietary manufacturing capabilities and a clear path to seek partnerships with major pharmaceutical companies for commercialization.

Autoimmune DiseasesType 1 DiabetesMultiple Sclerosis

Technology Platform

Platform for isolating, expanding, and engineering T-regulatory cells (Tregs) for autologous and allogeneic therapy, including next-generation CAR-Tregs for targeted immune suppression in autoimmune diseases.

Funding History

2

Total raised:$16M

Series A$10MMedicoverJun 15, 2021

Grant$6MEuropean UnionJun 15, 2020

Opportunities

The autoimmune disease market represents a multi-billion dollar opportunity with high unmet need for disease-modifying therapies.

PolTREG's integrated manufacturing facility provides a dual revenue opportunity from internal pipeline and CDMO services, while its platform technology allows expansion into numerous indications beyond its initial focus.

Risk Factors

High clinical development risk associated with novel cell therapies; reliance on future partnership deals for commercialization and funding; intense competition from well-funded biotechs also developing Treg and engineered cell therapies for autoimmunity.

Competitive Landscape

Competes in the emerging Treg therapy space with companies like Sangamo/Sanofi, Sonoma Biotherapeutics, GentiBio, and Abata Therapeutics. PolTREG differentiates through its long-term research heritage, clinical-stage assets in T1D/MS, and ownership of a strategic manufacturing facility in Europe.